Curated News
By: NewsRamp Editorial Staff
November 11, 2025
Oncotelic & Sapu Bioscience Unveil Breakthrough Nanoparticle Research
TLDR
- Oncotelic Therapeutics' sub-15 nm nanoparticles offer a competitive edge by overcoming delivery limitations of existing therapies, potentially leading to more effective cancer treatments.
- The review details how sub-15 nm nanoparticles achieve deeper tissue penetration, reduced organ accumulation, and enhanced diffusion across biological barriers including the blood-brain barrier.
- This nanoparticle technology could significantly improve cancer treatment outcomes and quality of life for patients by enabling more targeted, less toxic therapeutic delivery.
- Oncotelic's breakthrough research explores nanoparticles smaller than 15 nm, a size range that could revolutionize how medicines are delivered throughout the human body.
Impact - Why it Matters
This nanoparticle research represents a potential paradigm shift in drug delivery that could significantly improve treatment outcomes for patients with cancer, neurological disorders, and other conditions where conventional therapies struggle with delivery barriers. The ability of sub-15 nm particles to cross the blood-brain barrier opens new possibilities for treating brain tumors and neurological diseases that were previously considered untreatable with systemic medications. For patients, this could mean more effective treatments with fewer side effects, as the targeted delivery reduces accumulation in healthy organs. The faster renal clearance also addresses one of the major safety concerns in nanomedicine, potentially making these therapies safer for long-term use. This advancement could accelerate the development of precision medicines that deliver drugs exactly where needed while minimizing damage to healthy tissues.
Summary
Oncotelic Therapeutics (OTCQB: OTLC) and its joint venture partner Sapu Bioscience have achieved a significant scientific milestone with the publication of their groundbreaking review article "Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential" in the prestigious International Journal of Molecular Sciences. This comprehensive analysis, authored by a distinguished team including Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, represents the first thorough examination of nanoparticles exclusively within the 5-15 nm range—an emerging scale that promises to redefine nanomedicine. The review highlights how these sub-15 nm systems demonstrate superior performance characteristics including deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across critical biological barriers such as the blood-brain barrier.
As a clinical-stage biopharmaceutical company, Oncotelic Therapeutics focuses on developing innovative oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications. The company benefits from the extensive intellectual property portfolio of CEO Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal development programs, Oncotelic maintains strategic partnerships including a 45% ownership stake in GMP Bio, a joint venture that further strengthens the company's position in oncology and rare disease therapeutics. The publication of this nanoparticle research through the Dynamic Brand Portfolio of IBN underscores the company's commitment to advancing cutting-edge science while maintaining strong investor communication channels.
The breakthrough research establishes a new pharmacological paradigm that could overcome the delivery and toxicity limitations of both traditional small molecules and larger nanocarriers. This emerging size regime represents a potential game-changer for targeted drug delivery systems, particularly for treating challenging conditions where conventional therapies face significant barriers. The full details of this scientific advancement are available through the NetworkNewsWire platform, which provides comprehensive financial news and content distribution services as part of the InvestorBrandNetwork ecosystem. This publication marks an important step forward in nanomedicine research and demonstrates Oncotelic's leadership in developing next-generation therapeutic delivery technologies.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic & Sapu Bioscience Unveil Breakthrough Nanoparticle Research
